S. Stewart, K. Macintyre, and D. Hole, More ???malignant??? than cancer? Five-year survival following a first admission for heart failure, European Journal of Heart Failure, vol.35, issue.suppl A, pp.315-337
DOI : 10.1016/S1388-9842(00)00141-0

D. Logeart, Insuffisance cardiaque et dosage du BNP en pratique clinique. Spectra biologie n° 157 Janv -Fév -Mars, 2007.

A. Michalsen, G. Konig, and W. Thimme, Preventable causative factors leading to hospital admission with decompensated heart failure, Heart, vol.80, issue.5, pp.437-478, 1998.
DOI : 10.1136/hrt.80.5.437

C. and M. Cardiovasculaires, Société Française de Cardiologie, Editions Masson, pp.633-739, 2007.

A. Cohen-solal, Guide pratique de l'insuffisance cardiaque. Collection Médiguides, p.132, 2006.

C. Lien, N. Gillespie, A. Struthers, and M. Mcmurdo, Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas, European Journal of Heart Failure, vol.333, issue.1
DOI : 10.1016/S1388-9842(01)00200-8

G. Jondeau, Les difficult??s du diagnostic de l???insuffisance cardiaque du sujet ??g??, La Presse M??dicale, vol.33, issue.16, pp.1083-1088, 2004.
DOI : 10.1016/S0755-4982(04)98852-5

W. Remme and K. Swerdberg, Comprehensive guidelines for the diagnosis and treatment of chronic heart failure Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology, European Journal of Heart Failure, vol.22, issue.1, pp.22-1527, 2001.
DOI : 10.1016/S1388-9842(01)00231-8

P. Jourdain, Benefits of BNP plasma levels for optimising therapy in patients with systolic heart failure : the STARS-BNP multicenter randomised study, J.Am. Coll

K. Ho, J. Pinsky, W. Kannel, and D. Levy, The epidemiology of heart failure: The Framingham Study, Journal of the American College of Cardiology, vol.22, issue.4, pp.6-13, 1993.
DOI : 10.1016/0735-1097(93)90455-A

X. Jouven and M. Desnos, Epidémiologie des insuffisances cardiaques. Rev Prat, 2002.

R. Isnard and M. Komajda, Insuffisance cardiaque Aspects épidémiologiques, cliniques et pronostiques, Encycl Méd Chir Cardiologie, vol.11, p.17, 2003.

M. Van-der-wal, T. Jaarsma, and D. Van-veldhuisen, Non-compliance in patients with heart failure; how can we manage it?, European Journal of Heart Failure, vol.8, issue.28, pp.5-17, 2005.
DOI : 10.1016/j.ejheart.2004.04.007

J. Feenstra, D. Grobbee, and W. Remme, Drug-induced heart failure, Journal of the American College of Cardiology, vol.33, issue.5, pp.1152-62, 1999.
DOI : 10.1016/S0735-1097(99)00006-6

C. Good, L. Mcdermott, and B. Mccloskey, Diet and serum potassium in patients on ACE-inhibitors, JAMA, vol.274, issue.538, 1995.

S. Européenne-de-cardiologie, Groupe de travail pour le diagnostic et le traitement de l'insuffisance cardiaque chronique. Recommandations pour le diagnostic et le traitement de l'insuffisance cardiaque congestive, Arch Mal Coeur, vol.99, issue.2, 2006.

. Australia, New Zealand Heart Failure Research Collaborative Group. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease, Lancet, vol.349, pp.375-80, 1997.

E. Erdmann, P. Lechat, and P. Verkenne, Results from post-hoc analyses of the ClBISIl trial: effect of bisoprolol in high-risk patient groups with CHF, Eur J Heart Fail, vol.3, pp.469-79, 2001.

M. Packer, G. Antonopoulos, and J. Berlin, Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis, American Heart Journal, vol.141, issue.6
DOI : 10.1067/mhj.2001.115584

M. Flather, M. Shibata, and A. Coats, Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS), European Heart Journal, vol.26, issue.3, pp.215-240, 2005.
DOI : 10.1093/eurheartj/ehi115

F. Zannad, J. Mcmurray, H. Krum, D. Van-veldhuisen, K. Swedberg et al., Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms, New England Journal of Medicine, vol.364, issue.1
DOI : 10.1056/NEJMoa1009492

D. Juurlink, M. Mamdani, and D. Lee, Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study, New England Journal of Medicine, vol.351, issue.6, pp.543-51, 2004.
DOI : 10.1056/NEJMoa040135

J. Cohn and G. Tognoni, A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure, New England Journal of Medicine, vol.345, issue.23, pp.1667-1675, 2001.
DOI : 10.1056/NEJMoa010713

B. Olofsson, S. Yusuf, and M. Pfeffer, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial, Lancet, vol.362, pp.767-771, 2003.

J. Bayliss, M. Norell, and R. Canepa-anson, Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics., Heart, vol.57, issue.1, pp.17-22, 1987.
DOI : 10.1136/hrt.57.1.17

K. Channer, K. Mclean, and P. Lawson-matthew, Combination diuretic treatment in severe heart failure: a randomised controlled trial., Heart, vol.71, issue.2, pp.146-50, 1994.
DOI : 10.1136/hrt.71.2.146

A. Khand, A. Rankin, and G. Kaye, Systematic review of the management of atrial fibrillation in patients with heart failure, European Heart Journal, vol.21, issue.8, pp.614-646, 2000.
DOI : 10.1053/euhj.1999.1767

A. Khand, A. Rankin, and W. Martin, Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?, Journal of the American College of Cardiology, vol.42, issue.11, pp.1944-51, 2003.
DOI : 10.1016/j.jacc.2003.07.020

J. G. Cleland, The EuroHeart Failure survey programme???a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis, European Heart Journal, vol.24, issue.5, pp.442-63, 2003.
DOI : 10.1016/S0195-668X(02)00823-0

. Anaes, Méthode d'évaluation globale du risque cardiovasculaire, Service évaluation des technologies ; Version 2, 2004.

W. Bakrisgl and . Mr, Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause for concern ? Arch InternMed, pp.685-93, 2000.

A. Maggioni, . Mckelviers, . Pinail, J. Soler-soler, and K. Swedberg, Pratical recommendations for the use ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure : Putting guidelines into practice, Eur J Heart Fail, vol.7, pp.710-731, 2005.

J. Robert and . Mentz, ? blockers for heart failure: which works best? There seems to be a class effect; " some blocker is better than no blocker Anti-aldostérone et insuffisance cardiaque, Flammarion médecine, BMJ, vol.346, pp.480-523, 2005.

B. Pitt, F. Zannad, and W. Remme, The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure, New England Journal of Medicine, vol.341, issue.10, pp.709-717, 1999.
DOI : 10.1056/NEJM199909023411001

K. Weber, Aldosterone and Spironolactone in Heart Failure, New England Journal of Medicine, vol.341, issue.10, pp.753-755, 1999.
DOI : 10.1056/NEJM199909023411009

F. Dievart and . Réalités-cardiologique, Congrès de la société européenne de cardiologie : Etude SHIFT : l'ivabradine devient un traitement de l'insuffisance cardiaque, 2010.

K. Fox, I. Ford, P. Steg, M. Tendera, and R. Ferrari, Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial, The Lancet, vol.372, issue.9641, pp.807-816, 2008.
DOI : 10.1016/S0140-6736(08)61170-8

A. Cohen-solal, A national survey of heart failure in French hospitals. The Myocardiopathy and Heart Failure Working Group of the French Society of Cardiology, the National College of General Hospital Cardiologists and the

H. Inpes, Guide méthodologique : Structuration d'un programme d'éducation thérapeutique du patient dans le champ des maladies chroniques, 2007.

W. Miller, Synthèse des facteurs prédictifs de placement en institution de personnes âgées de 65 et plus, 2000.